JEIL PHARMACEUTICAL secures South Korea rights for Shionogis antibiotic Petrozajoo JEIL PHARMACEUTICAL prepares to enhance ...

A digital therapeutic (DTx) for attention deficit hyperactivity disorder (ADHD) developed by Akili has been approved in Japan, where it will be sold by licensee Shionogi.

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

The obesity market size is projected to witness growth from 2024 to 2034 due to the rising prevalence of obesity. This expansion is expected to be further influenced by the extensive pipeline of ...

A clinical trial by Shionogi is a milestone in the search to treat Jordan's Syndrome, a rare genetic disorder named after a California lobbyist's daughter.

A growth occurring in the next five years will be fuelled by the launch of two high-priced pipeline products providing ...

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...

According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...

While most pharma companies have exited the antibiotics area, Japanese drugmaker Shionogi has stuck with it and has just expanded its pipeline with a deal to buy US biotech Qpex Biopharma.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a biotechnology company focused on developing small molecule drugs for viral infections and liver diseases, is navigating a critical phase in its evolution.